|Bid||133.65 x 100|
|Ask||133.68 x 300|
|Day's Range||131.72 - 133.92|
|52 Week Range||94.42 - 135.18|
|PE Ratio (TTM)||50.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.
Biotechs and desktop software led the market, while Boeing fared well at the Paris Air Show, oil kept falling, China cracked down on Weibo.
Kite Pharma, Celgene, and Acadia Pharmaceuticals are three biotech stocks that should be on enterprising investors' radars. Here's why.